<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>1302725</identifier>
<setSpec>0016-3813</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Novelo, B</dc:author>
<dc:author>Galván Plata, M E</dc:author>
<dc:author>Arellano, J</dc:author>
<dc:author>Lizola Margolis, I</dc:author>
<dc:author>MacGregor Gooch, J</dc:author>
<dc:author>Vázquez Salas, L</dc:author>
<dc:description xml:lang="en">94 patients with renal allograft from a living related donor were studied in three different groups: 1 Patients with identical histocompatibility (n-32), treated with prednisone (PDN) and azathioprine (Aza); 2 Haploidentical patients (34) who received PDN, Aza and cyclosporine (CsA); 3 Haploidentical patients (28) who previous to the transplantation received specific donor blood transfusions and Aza/PDN after the transplantation. The survival for the patient and the graft after five years was 100% and 96% in group 1; 97% y 89% in group 2 and 82% and 72% in group 3. Five patients in group 1 received CsA also. There was no mortality in group 1, while there were one death in group 2 and two more in group 3. There was no significant difference between CsA and Blood transfusions in the patients and grafts survival.</dc:description>
<dc:type>Comparative Study</dc:type>
<dc:language>es</dc:language>
<dc:date>1992 May-Jun </dc:date>
<dc:title xml:lang="es">Inmunosupresión y transfusiones sanguíneas en pacientes con trasplante renal.</dc:title>
<dc:title xml:lang="en">[Immunosuppression and blood transfusions in patients with a kidney transplant].</dc:title>
<dc:publisher>Gaceta medica de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
